¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 Á¦34Â÷ ´ëÇÑÇ÷¾×ÇÐȸ ¸²ÇÁÁ¾¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-04-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 Á¦34Â÷ ´ëÇÑÇ÷¾×ÇÐȸ ¸²ÇÁÁ¾¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-04-20
±³À°ÀÏÀÚ : 2024-04-20
±³À°Àå¼Ò : ·Ôµ¥¿ùµåŸ¿ö SKY31 ÄÁº¥¼Ç

±³À°ÁÖÁ¦ : 2024 Á¦34Â÷ ´ëÇÑÇ÷¾×ÇÐȸ ¸²ÇÁÁ¾¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸²ÇÁÁ¾¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 5ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í ºñȸ¿ø 50,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 20ÀÏ ROOM1 10:30~11:05 Basic Concept, Methodology and Preclinical Models of ImmunoPET ÀÌ°æÇÑ(¼º±Õ°üÀÇ´ë )

±³À°½Ã°£ 04¿ù 20ÀÏ ROOM1 11:05~11:40 Clinical Application of ImmunoPET in Cance °­¼¼·É(Àü³²ÀÇ´ë )

±³À°½Ã°£ 04¿ù 20ÀÏ ROOM1 11:40~12:30 Clinical Trials and Development Utilizing Generative A ÃÖ¼öÀÎ(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 04¿ù 20ÀÏ ROOM1 13:30~14:10 CAR-Engineered T Cell Therapy Stephen J. Schuster (University of Pennsylvania)

±³À°½Ã°£ 04¿ù 20ÀÏ ROOM1 14:10~14:50 Bispecific Antibody Therapy Georgios Spitadakis(Roche)

±³À°½Ã°£ 04¿ù 20ÀÏ ROOM1 15:10~15:45 Novel Monoclonal Antibodies and Antibody-Drug Conjugates À¯ÄèÇÑ(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ ROOM1 15:45~16:20 CAR-Engineered T Cell Therapy Àü¿ë¿ì(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 04¿ù 20ÀÏ ROOM1 16:20~16:55 Bispecific Antibody Therapy Á¤Á¾Çå(±¹¸³¾Ï¼¾ÅÍ )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 Á¦34Â÷ ´ëÇÑÇ÷¾×ÇÐȸ ¸²ÇÁÁ¾¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-04-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2024³â Á¦11ȸ °­µ¿°æÈñ ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¾ö : 2024-04-20
´ÙÀ½±Û Á¦4Â÷ ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ ½ÉÆ÷Áö¾ö : 2024-04-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20507 ºÎ»ê ´ëÇÑÁ¤Çü¿Ü°ú ºÎ»ê․¿ï»ê․°æ³²Áöȸ Á¦361Â÷ ¿ù·ÊÇмúȸ : 2024-05-14 0 94 2024-04-29
20506 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ½ÉÆ÷Áö¾ö-¼­¿ï(°­³²) : 2024-05-14 0 121 2024-04-29
20505 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø Æó ¿¬¼ö°­Á : 2024-05-14 0 117 2024-04-29
20504 ¼­¿ï (1ÀÏÂ÷) ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ 2024³â Ãá°è½ÉÆ÷Áö¾ö : 2024-05-13 0 66 2024-04-29
20503 ´ëÀü Çѱ¹¿©ÀÚÀÇ»çȸ ´ëÀüÁöȸ 5¿ù Çмú½ÉÆ÷Áö¾ö(¾î±ú ÅëÁõÀÇ ¿øÀΰú Ä¡·á) : 2024-05-13 0 55 2024-04-29
20502 °æ±â (¿Â¶óÀÎ) Á¦1Â÷ ±ºÆ÷½ÃÀÇ»çȸ Çмú´ëȸ : 2024-05-12 0 115 2024-04-29
20501 ¼­¿ï Á¦12ȸ ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-12 0 72 2024-04-29
20500 ¼­¿ï 2024 Á¦2Â÷ ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸºÎÀοµ»ó¿¬±¸ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-12 0 79 2024-04-29
20499 ¼­¿ï Çѱ¹Á¤½ÅÄ¡·áÇÐȸ Á¤½ÅÄ¡·á Áõ·Ê¹ßÇ¥ : 2024-05-11 0 118 2024-04-29
20498 ºÎ»ê ¸¸¼ºÆó¼â °ü»óµ¿¸Æ ÁßÀç½Ã¼ú¿¬±¸È¸ The 23rd K-CTO(Korean Chronic Total Occlusion Club) Live Demonstration : 2024-05-11 0 80 2024-04-29
20497 ¼­¿ï ´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11 0 121 2024-04-29
20496 ¼­¿ï 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-11 0 54 2024-04-29
20495 ¼­¿ï Á¦77Â÷ ´ëÇÑû°¢ÇÐȸ Çмú´ëȸ : 2024-05-11 0 111 2024-04-29
20494 ÀÎõ Á¦9ȸ °¡Ãµ´ë ±æº´¿ø ½Å°æ¿Ü°ú ¾÷µ¥ÀÌÆ® ½ÉÆ÷Áö¿ò (G-NeUS) : 2024-05-11 0 107 2024-04-29
20493 ´ëÀü 2024³â ´ëÇѽŰæÁßÀçÄ¡·áÀÇÇÐȸ Ãá°èÇмú´ëȸ & Basic Training Course : 2024-05-11 0 89 2024-04-29
41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷